Google
BSX Stock Analysis — BOSTON SCIENTIFIC CORP (Healthcare >> Medical Devices)
BSX FAQ
What is BSX's P/E ratio?
BOSTON SCIENTIFIC CORP (BSX) currently trades at a P/E ratio of 18.65.
What is BSX's ROE?
BOSTON SCIENTIFIC CORP reports a Return on Equity (ROE) of 213.56%.
What is BSX's dividend yield?
BOSTON SCIENTIFIC CORP offers a dividend yield of 0.00%.
What is BSX's Quality Score?
Our AI rates BSX's overall financial quality at 100 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BSX?
Our AI Timing Score for BSX is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BSX belong to?
BOSTON SCIENTIFIC CORP is classified under the Healthcare >> Medical Devices sector on the NYSE exchange
BSX AI Analysis Summary
Our AI summary for BSX: BOSTON SCIENTIFIC CORP (NYSE), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 18.65, ROE of 213.56%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 46.73
Price
0.73
(1.59%)
Day Change
|
|
|---|
BSX, the overall quality is excellent ( Quality = 100) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Excellent
- Reason
-
Company financial health is Excellent from almost all quality indicators
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
67% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
1123
|
| Magic Formula Rank by ROE |
1123
|
| Magic Formula Rank by ROIC |
1543
|
| Price | 46.73 |
| PBV / Sector |
39.82 / -101.57
|
| Earning Per Share | 2.51 |
| PE / Sector |
18.65 / 31.23
|
| PEG or PE/Growth / Sector |
0.29 / 0.40
GREAT
|
| Average 1M Daily Value |
793.06 M
|
| Average 1W Daily Value |
1,227.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
72% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:35 |
| Symbol | BSX |
| Name | BOSTON SCIENTIFIC CORP |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 1,486.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 68,372.34 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
Phone: 508 683 4000
Website: https://www.bostonscientific.com
Employees: 59,000
Sector: Healthcare >> Medical Devices
Description: Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
